Is Exact Sciences Corporation (EXAS)’s Fuel For Real? The Stock Just Increased Again

April 17, 2018 - By Michael Collier

Exact Sciences Corporation (NASDAQ:EXAS) Logo

Investors sentiment decreased to 0.88 in 2017 Q4. Its down 0.13, from 1.01 in 2017Q3. It turned negative, as 25 investors sold Exact Sciences Corporation shares while 105 reduced holdings. 44 funds opened positions while 70 raised stakes. 92.48 million shares or 1.24% less from 93.65 million shares in 2017Q3 were reported.
Raymond James Assocs holds 0.01% or 98,777 shares in its portfolio. X Mgmt Limited Company holds 1,003 shares. M&T Bank invested 0% in Exact Sciences Corporation (NASDAQ:EXAS). Moreover, Fisher Asset Llc has 0% invested in Exact Sciences Corporation (NASDAQ:EXAS). Rathbone Brothers Public Limited owns 12,800 shares. Shelton Mngmt has invested 0.03% in Exact Sciences Corporation (NASDAQ:EXAS). Amalgamated Bancorp stated it has 15,998 shares or 0.02% of all its holdings. Commercial Bank Of Ny Mellon Corporation reported 624,560 shares. Massachusetts Finance Com Ma has 175,315 shares. State Common Retirement Fund reported 0.01% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS). Susquehanna Gp Llp has invested 0% in Exact Sciences Corporation (NASDAQ:EXAS). Primecap Ca accumulated 3.58M shares. Moreover, Ameritas Partners Incorporated has 0.02% invested in Exact Sciences Corporation (NASDAQ:EXAS). 359,911 are owned by Amundi Pioneer Asset Mgmt. Marietta Investment holds 0.07% or 4,400 shares.

Since January 2, 2018, it had 0 insider purchases, and 20 insider sales for $24.73 million activity. $243,068 worth of Exact Sciences Corporation (NASDAQ:EXAS) was sold by ARORA MANEESH on Monday, February 26. Another trade for 25,319 shares valued at $1.07 million was made by Conroy Kevin T on Friday, February 23. $85,124 worth of Exact Sciences Corporation (NASDAQ:EXAS) was sold by COWARD D SCOTT on Saturday, March 31. $1.50 million worth of stock was sold by LIDGARD GRAHAM PETER on Monday, February 26. Zanotti Katherine S sold $325,440 worth of stock or 7,232 shares. Another trade for 3,098 shares valued at $126,925 was made by Doyle James Edward on Tuesday, April 10.

The stock of Exact Sciences Corporation (NASDAQ:EXAS) is a huge mover today! The stock increased 6.24% or $2.8 during the last trading session, reaching $47.68. About 2.74 million shares traded. Exact Sciences Corporation (NASDAQ:EXAS) has risen 81.43% since April 17, 2017 and is uptrending. It has outperformed by 69.88% the S&P500.
The move comes after 6 months positive chart setup for the $5.77 billion company. It was reported on Apr, 17 by Barchart.com. We have $49.11 PT which if reached, will make NASDAQ:EXAS worth $173.01M more.

Analysts await Exact Sciences Corporation (NASDAQ:EXAS) to report earnings on April, 26. They expect $-0.35 earnings per share, down 9.37 % or $0.03 from last year’s $-0.32 per share. After $-0.18 actual earnings per share reported by Exact Sciences Corporation for the previous quarter, Wall Street now forecasts 94.44 % negative EPS growth.

Exact Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

Among 12 analysts covering Exact Sciences (NASDAQ:EXAS), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. Exact Sciences had 25 analyst reports since October 19, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Friday, October 20 by Jefferies. Leerink Swann maintained Exact Sciences Corporation (NASDAQ:EXAS) rating on Tuesday, October 31. Leerink Swann has “Outperform” rating and $63 target. The company was maintained on Wednesday, December 20 by Cowen & Co. Canaccord Genuity maintained it with “Buy” rating and $55.0 target in Friday, February 23 report. The rating was maintained by Leerink Swann with “Buy” on Wednesday, March 28. The rating was maintained by Benchmark on Tuesday, October 31 with “Buy”. The firm has “Buy” rating by Bank of America given on Tuesday, October 31. The rating was maintained by Jefferies with “Buy” on Tuesday, March 27. The stock of Exact Sciences Corporation (NASDAQ:EXAS) has “Neutral” rating given on Monday, November 13 by Robert W. Baird. Bank of America maintained Exact Sciences Corporation (NASDAQ:EXAS) rating on Thursday, October 19. Bank of America has “Buy” rating and $56 target.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company has market cap of $5.77 billion. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer. It currently has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

Exact Sciences Corporation (NASDAQ:EXAS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.